ASP Isotopes Inc.

ASP Isotopes Inc. announced a proposed merger of its wholly-owned subsidiary, Noble Africa LLC, with a subsidiary of ENDRA Life Sciences Inc. Noble Africa, an intermediate holding company for Renergen Limited, will be the surviving entity and plans to operate as Noble Africa Inc., seeking a Nasdaq listing under "NOBA." Concurrently, Noble Africa has secured commitments for a private placement expected to raise approximately $50 million in gross proceeds, including $20 million from ASP Isotopes. The transaction aims to establish Renergen’s Virginia Gas Project as a dedicated, publicly traded helium platform.

ASP Isotopes Inc. announced that its wholly-owned subsidiary, Noble Africa LLC, an intermediate holding company for Renergen Limited, will merge with ENDRA Life Sciences Inc. The combined entity, Noble Africa Inc., aims to become a Nasdaq-listed helium platform for Renergen’s Virginia Gas Project. The transaction includes a concurrent private placement expected to raise $50 million, with ASP Isotopes investing $20 million. Upon completion, ASP Isotopes is projected to own approximately 89% of the combined company.

ASP Isotopes Inc. announced that Tetra4 Proprietary Limited, a subsidiary of Renergen Limited, has entered into its first take-or-pay contract for the supply of contained helium. The five-year agreement with an Asian industrial gases company is priced at over $600/MCF and covers approximately 15% of the Virginia Gas Project's Phase 1 expected nameplate capacity. Commercial operations for Phase 1 are targeted for Q3 2026, with Phase 2 construction, which is 13 times larger, expected to begin in 2H 2026, supported by up to $750 million in conditional debt financing. The company highlighted the critical global helium supply disruption, positioning the project as a vital contributor to diversifying supply.

ASP Isotopes Inc. announced that its subsidiary, Tetra4, secured its first five-year take-or-pay contract to supply contained helium from the Virginia Gas Project to an Asian industrial gases company. This contract, priced at over $600/MCF, establishes multi-year cash flow for Phase 1, which is targeted for commercial operations in Q3 2026. The company is also progressing with Phase 2 development, expected to be 13 times larger than Phase 1, and highlights the project's importance amid global helium supply disruptions.

ASP Isotopes Inc. announced the successful restart of the first 18 stages of its Silicon-28 enrichment facility in Pretoria, South Africa, following nine months of engineering enhancements to non-core components. These stages have operated for over three weeks at target enrichment levels, leading the engineering team to believe an optimized solution has been found. The company expects to implement these enhancements to the remaining stages and commence initial commercial shipments of enriched Silicon-28 in Q3 2026, fulfilling three existing commercial contracts with U.S. customers.

ASP Isotopes Inc. announced the release of its latest investor presentation on May 20, 2026. The presentation is accessible on the company's website and contains information current as of its release date, with no obligation for future updates. The company clarified that the presentation is not deemed "filed" under certain sections of the Securities Exchange Act and includes standard "safe harbor" language for forward-looking statements.

ASP Isotopes Inc. reported a net loss attributable to shareholders of $(6.88) million for Q1 2026, an improvement from $(8.45) million in Q1 2025. Total revenue significantly increased by 279% to $4.18 million. The company completed the acquisition of Renergen in January 2026, expanding into liquid helium and LNG production, and deconsolidated its subsidiary Skyline. ASP Isotopes also made progress on its isotope enrichment platforms, targeting initial commercial shipments for C-14, Si-28, and Yb-176 in mid-2026 to Q3 2026.

ASP Isotopes Inc.'s wholly-owned subsidiary, Quantum Leap Energy (QLE), has entered into a non-binding Memorandum of Understanding (MOU) with a European nuclear technology company specializing in advanced nuclear reactor development. The MOU outlines a framework for collaboration to supply High Assay Low Enriched Uranium (HALEU) to the European partner, with potential deliveries beginning in 2028 and scaling up through 2036. This agreement is a significant step in QLE's mission to build enrichment capabilities and address the critical challenge of HALEU supply for the advanced nuclear industry.

ASP Isotopes Inc. announced that its wholly-owned subsidiary, Quantum Leap Energy LLC (QLE), has appointed Dr. Peter S. Fiske to its Strategic Advisory Board. Dr. Fiske's extensive background in technology commercialization, advanced materials, and government partnerships is expected to bolster QLE's expansion in government and commercial nuclear energy markets. This strategic appointment is part of QLE's accelerating organizational development, which also includes the recent formation of its Strategic Advisory Board, the appointment of a Chief Technology Officer, and a collaboration with the University of Bristol for a new lithium laser research facility.

ASP Isotopes Inc. filed an amendment to its 2025 Form 10-K to include Part III information, which was previously omitted due to the delayed filing of its definitive proxy statement. The amendment provides detailed information on the company's board of directors, executive officers, and their compensation for 2025 and 2024. CEO Paul Mann's total compensation for 2025 was $16.8 million, including a $600,000 bonus and $15.5 million in stock awards, while CFO Heather Kiessling and COO Robert Ainscow also received significant compensation.